Uterine Fibroids Therapeutics
1. Ella patent expiration
Treatment: Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of ...
ELLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8962603 | LAB HRA | Method for post coital contraception in overweight or obese female subjects using ulipristal acetate |
Jun, 2030
(4 years from now) | |
| US8426392 | LAB HRA | Method for providing emergency contraception |
Jun, 2030
(4 years from now) | |
| US9283233 | LAB HRA | Method for on-demand contraception |
Apr, 2030
(4 years from now) | |
| US8735380 | LAB HRA | Ulipristal acetate tablets |
Feb, 2029
(2 years from now) | |
| US10159681 | LAB HRA | Method for on-demand contraception |
Apr, 2030
(4 years from now) | |
| US9844510 | LAB HRA | Ulipristal acetate tablets |
Dec, 2028
(2 years from now) | |
| US10772897 | LAB HRA | Method for on-demand contraception |
Apr, 2030
(4 years from now) | |
| US8512745 | LAB HRA | Ulipristal acetate tablets |
Jun, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2015 |
| M(M-271) | Jun 24, 2024 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
NCE-1 date: 13 August, 2014
Market Authorisation Date: 13 August, 2010
Dosage: TABLET
How can I launch a generic of ELLA before it's drug patent expiration?
More Information on Dosage
ELLA family patents
2. Orgovyx patent expiration
Treatment: Treatment of adult patients with advanced prostate cancer; Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate c...
ORGOVYX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7300935 | SUMITOMO AM | Thienopyrimidine compounds and use thereof |
Jan, 2029
(2 years from now) | |
| US11795178 | SUMITOMO AM | Compositions of thienopyrimidine derivatives |
Sep, 2033
(7 years from now) | |
| US12325714 | SUMITOMO AM | Compositions of thienopyrimidine derivatives |
Sep, 2033
(7 years from now) | |
| US8058280 | SUMITOMO AM | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2026
(24 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11583526 | SUMITOMO AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US8735401 | SUMITOMO AM | Thienopyrimidine compounds and use thereof |
Feb, 2024
(2 years ago) | |
| US10449191 | SUMITOMO AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US10786501 | SUMITOMO AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US12336990 | SUMITOMO AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US12144809 | SUMITOMO AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US12097198 | SUMITOMO AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US10350170 | SUMITOMO AM | Solid preparation |
Feb, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Dosage: TABLET
How can I launch a generic of ORGOVYX before it's drug patent expiration?
More Information on Dosage
ORGOVYX family patents